Premium
L. reuteri NCIMB 30242: The Sunshine Probiotic ?
Author(s) -
Jones Mitchell L.,
Martoni Christopher J.,
Prakash Satya
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1079.17
Subject(s) - lactobacillus reuteri , probiotic , placebo , medicine , cholesterol , vitamin d and neurology , food science , biology , bacteria , genetics , alternative medicine , pathology
Background/Objectives Low serum 25‐hydroxyvitamin D (25(OH)D) is a risk factor for cardiovascular disease (CVD). Bile salt hydrolase (BSH) – active Lactobacillus reuteri NCIMB 30242 capsules have been shown to lower cholesterol and reduce sterol absorption; however their effect on fat soluble vitamins are unknown and the main objective of this study. Hypothesis The research hypothesis is that L. reuteri NCIMB 30242 capsules would not significantly alter serum fat soluble vitamins in a randomized controlled trial. Methods 127 subjects were randomized to consume L. reuteri NCIMB 30242 or placebo capsules over a 9‐week intervention period. Results Oral supplementation of L. reuteri NCIMB 30242 capsules did not result in reduced serum vitamins A, E and â‐carotene and unexpectedly increased 25(OH)D. Despite no differences in dietary intake (P>;0.05), subjects consuming L. reuteri NCIMB 30242 showed increased serum 25(OH)D over the intervention period by 14.9 nmol/l or 25.5%, which was a significant mean change relative to placebo of 17.1 nmol/l (P=0.005) or 22.4% respectively (P=0.011). Changes in 25(OH)D were negatively correlated with hs‐CRP (r = −0.208, P=0.023). Conclusions To our knowledge this is the first report of increased serum 25(OH)D with oral probiotic supplementation. L. reuteri NCIMB 30242 should be considered for improving vitamin D status in individuals with CVD.